First Insight, TriZetto’s Gateway team to enhance reimbursement cycle

Article

MaximEyes customers will soon experience revenue cycle management enhancements.

Hillsboro, OR-First Insight Corp. has partnered with TriZetto Corp.’s Gateway EDI subsidiary to provide revenue cycle management services to ophthalmic practices. According to a press release issued by the companies, the collaboration will enable practices to process claims and collect reimbursement more effectively.

First Insight’s MaximEyes practice management software and EHR system, integrated with TriZetto’s electronic claims, allows practices to send claims automatically and electronically over a secure channel, get paid more quickly and accurately, and reduce errors in the billing process. Once claims are sent, practices can retrieve a claims response report that shows the initial status of the claims, enabling offices to tackle claims rejections quickly. Because the TriZetto and MaximEyes platforms will be integrated, practices will also be able to eliminate paperwork by storing and accessing all Electronic Remittance Advice (ERA) files electronically.

In addition to electronic claims and ERA management, TriZetto will soon integrate its electronic patient statements with First Insight’s MaximEyes software, allowing providers to easily send patient statements quickly to maintain strong cash flow. The companies also will provide MaximEyes customers with the ability to verify patients’ insurance eligibility electronically.

Recent Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Pediatric optometrist Dr. Magdela Stec speaks about myopia management at EyeCon 2024
Dr. Mark Dunbar chats about his EyeCon 2024 presentation about diabetic eye care
Dr. Khanh Hoang at EyeCon 2024 receiving the Visionary in Eye Care Award
Dr Adam Wenick at EyeCon 2024
David Chin Yee, MD, at EyeCon 2024
Dr. Adam Ramsey discusses innovation for your eye care practice at EyeCon 2024
Dr. Leonard Messner at EyeCon 2024
Dr. Adam Wenick at EyeCon 2024
EyeCon 2024: Insights on transforming ocular surface disease management
© 2024 MJH Life Sciences

All rights reserved.